Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
The second-quarter 2026 reporting cycle of the Medical sector is currently in full swing. The sector mainly comprises pharma/biotech and medical device companies.
AMGN - Amgen Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$364.71
DETAILS
HIGH:
$427.00
LOW:
$303.00
MEDIAN:
$360.00
CONSENSUS:
$364.71
DOWNSIDE:
3.74%
Stock News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Alpine Woods Capital Investors LLC Purchases 4,003 Shares of Amgen Inc. $AMGN
Alpine Woods Capital Investors LLC boosted its position in Amgen Inc. (NASDAQ: AMGN) by 21.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,064 shares of the medical research company's stock after buying an additional 4,003 shares during the
Amgen discloses data breach, says patient information was stolen
Drugmaker Amgen suffered a cybersecurity breach where hackers stole company data and patient health information from cloud storage systems run by third-party providers, it said in a regulatory filing on Friday.
ПОЛОЖИТЕЛЬНАЯ ОЦЕНКА CHMP ПОДДЕРЖИВАЕТ БОЛЕЕ ШИРОКОЕ ПРИМЕНЕНИЕ ПРЕПАРАТА REPATHA® КОМПАНИИ AMGEN ДЛЯ СНИЖЕНИЯ РИСКА ПЕРВОГО ИНФАРКТА ИЛИ ИНСУЛЬТА
/PRNewswire/ -- Компания Amgen (NASDAQ: AMGN) сегодня объявила, что Комитет по лекарственным препаратам для медицинского применения (CHMP) Европейского
Amgen Q2 Earnings Preview: Will the Beat Streak Continue?
Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.
KLADNÉ STANOVISKO CHMP PODPORUJE ŠIRŠÍ POUŽITÍ PŘÍPRAVKU REPATHA® SPOLEČNOSTI AMGEN PŘED PRVNÍM INFARKTEM NEBO MOZKOVOU MRTVICÍ
/PRNewswire/ -- Společnost Amgen (NASDAQ: AMGN) dnes oznámila, že Výbor pro léčivé přípravky pro humánní použití (CHMP) Evropské agentury pro léčivé přípravky
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif., July 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the third quarter of 2026.
POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA® VOR ERSTEM HERZINFARKT ODER SCHLAGANFALL
/PRNewswire/ -- Amgen (NASDAQ: AMGN) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, CHMP) der
What Analyst Projections for Key Metrics Reveal About Amgen (AMGN) Q2 Earnings
Besides Wall Street's top-and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task.
AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., July 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets.
Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Everest Financial Group LLC Takes Position in Amgen Inc. $AMGN
Everest Financial Group LLC purchased a new stake in Amgen Inc. (NASDAQ: AMGN) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,505 shares of the medical research company's stock, valued at approximately $530,000. Other hedge funds and
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos
Amgen said on Friday it submitted new evidence to the FDA on July 23 as it seeks a hearing to challenge the proposed withdrawal of its rare-disease drug Tavneos from the U.S. market.
Bank of Nova Scotia Has $110.56 Million Stock Position in Amgen Inc. $AMGN
Bank of Nova Scotia reduced its holdings in Amgen Inc. (NASDAQ: AMGN) by 15.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 314,227 shares of the medical research company's stock after selling 58,745 shares during the period.
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Amgen (AMGN) concluded the recent trading session at $371.47, signifying a +1.48% move from its prior day's close.
Verizon Was Booted From the Dow – 5 Dividend Giants Got the Same Treatment and Eventually Soared
Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
Price Targets
Amgen price target raised to $360 from $350 at Barclays
$360.00
(was $393.10)
Emily Field
·
Barclays
Amgen price target raised to $420 from $400 at UBS
$420.00
(was $358.68)
UBS
Amgen (AMGN) PT Raised to $343 at GuggenheimMember Login
$343.00
(was $363.39)
Guggenheim
Amgen price target lowered to $333 from $340 at Morgan Stanley
$333.00
(was $368.10)
Morgan Stanley
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
$400.00
(was $362.45)
Evan David Seigerman
·
BMO Capital
Amgen (AMGN) PT Raised to $303 at Mizuho
$303.00
(was $350.53)
Salim Syed
·
Mizuho Securities
Amgen (AMGN) PT Raised to $340 at Morgan StanleyMember Login
$340.00
(was $344.56)
Morgan Stanley
Amgen price target lowered to $389 from $425 at Goldman Sachs
$389.00
(was $352.62)
Goldman Sachs
Amgen price target lowered to $427 from $432 at Piper Sandler
$427.00
(was $336.45)
Piper Sandler
Amgen price target lowered to $340 from $351 at Guggenheim
$340.00
(was $329.82)
Guggenheim
Amgen price target raised to $332 from $326 at Morgan Stanley
$332.00
(was $329.31)
Morgan Stanley
Amgen initiated with a Hold at Canaccord
$366.00
(was $350.16)
Canaccord Genuity
Amgen price target raised to $326 from $309 at Morgan Stanley
$326.00
(was $352.59)
Terence Flynn
·
Morgan Stanley
Amgen price target raised to $351 from $347 at Guggenheim
$351.00
(was $355.60)
Guggenheim
Amgen price target raised to $325 from $319 at Truist
$325.00
(was $349.81)
Truist Financial
Jefferies Starts Amgen (AMGN) at Hold
$350.00
(was $373.07)
Akash Tewari
·
Jefferies
Leerink Partners Reiterates Market Perform Rating on Amgen (AMGN), lowers estimates
$355.00
(was $367.60)
David Risinger
·
Leerink Partners
Amgen initiated with an Equal Weight at Barclays
$185.00
(was $375.50)
Barclays
Amgen price target raised to $375 from $325 at Wells Fargo
$375.00
(was $379.73)
Wells Fargo
Amgen price target raised to $432 from $381 at Piper Sandler
$432.00
(was $373.36)
Piper Sandler